Summary: Michael Mithoefer, M.D., of MAPS Public Benefit Corporation (MAPS PBC) joins Newsy’s Clayton Sandell on The Why to discuss MAPS’ research of MDMA-assisted therapy for PTSD. Dr. Mithoefer emphasizes the importance of a controlled environment for MDMA-assisted therapy, as opposed to a take-home drug model, and explains that the legal barriers to psychedelic research were put in place “based on political considerations, not scientific or medical considerations.”
Newsy: More Doctors Are Embracing Psychedelics
